Back to top

Raymond James Analyst Maintains Buy on Praxis, Sees PDUFA Extension as Manageable While Trimming Price Target from $731 to $719

In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Praxis Precision Medicines, with a price target of $...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Praxis Precision Medicines, Inc. (PRAX)